Pfizer Completes $3.2 Billion Full Exit from Haleon with Sale of Remaining 7.3% Stake

Recently, Pfizer sold its stake in the consumer healthcare company.All Remaining Shares of Haleon, totaling approximately 662 million ordinary shares, representing 7.3% of Haleon's total share capital.

Pfizer will pay per share385 penceSold approximately 618 million shares to investment institutions at a certain price, and another 44 million shares were sold directly to Haleon at the same price, for a total amount of £2.55 billion.(Approximately USD 3.2 billion)。

Source: Foreign media

In December 2018, GSK and Pfizer joined forces to merge their consumer healthcare businesses into Haleon. At that time, GSK held 68% of the shares in the joint venture, while Pfizer held 32%. In July 2022, Haleon was officially spun off from GSK and subsequently listed on both the London Stock Exchange and the New York Stock Exchange.

After becoming independent, Pfizer and GSK continued to reduce their holdings. In May 2024, GSK announced the completion of the sale of all Haleon shares, fully exiting the consumer healthcare sector. Now, Pfizer has followed suit by selling all of its Haleon shares through multiple reductions.

Cover Source:Company Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！